Brokerages Set Pulmonx Co. (NASDAQ:LUNG) Target Price at $12.75

Pulmonx Co. (NASDAQ:LUNG) has received a consensus rating of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $12.75.

A number of equities research analysts have commented on LUNG shares. Stifel Nicolaus decreased their price objective on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, October 31st. Citigroup reissued a “neutral” rating and set a $7.50 price target (down from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company dropped their price objective on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th.

Pulmonx Stock Performance

NASDAQ LUNG opened at $6.15 on Wednesday. Pulmonx has a 1-year low of $5.46 and a 1-year high of $14.84. The company has a 50 day moving average of $6.50 and a 200-day moving average of $6.84. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The firm has a market cap of $242.85 million, a price-to-earnings ratio of -4.18 and a beta of 0.69.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.07. The firm had revenue of $20.39 million during the quarter, compared to the consensus estimate of $20.39 million. Pulmonx had a negative return on equity of 53.88% and a negative net margin of 72.01%. During the same quarter in the previous year, the company posted ($0.39) EPS. On average, equities analysts forecast that Pulmonx will post -1.53 earnings per share for the current fiscal year.

Insider Activity at Pulmonx

In other Pulmonx news, Director Glendon E. French III sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $6.63, for a total value of $132,600.00. Following the completion of the sale, the director now owns 1,071,974 shares of the company’s stock, valued at approximately $7,107,187.62. This represents a 1.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel David Aaron Lehman sold 5,497 shares of Pulmonx stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $6.19, for a total transaction of $34,026.43. Following the transaction, the general counsel now directly owns 197,851 shares in the company, valued at approximately $1,224,697.69. This represents a 2.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 49,873 shares of company stock worth $324,070 over the last ninety days. Company insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Pulmonx

A number of hedge funds have recently modified their holdings of LUNG. 272 Capital LP bought a new stake in Pulmonx during the 3rd quarter worth approximately $25,000. nVerses Capital LLC acquired a new position in shares of Pulmonx in the third quarter valued at approximately $26,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Pulmonx during the second quarter worth $37,000. SG Americas Securities LLC acquired a new stake in shares of Pulmonx during the third quarter worth $102,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Pulmonx during the second quarter worth $93,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.